Tamnorzatinib clinical trials
Also written ONO-7475.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses tamnorzatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ONO-7475
- 3
Studies by the year they started
4 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Ono Pharmaceutical Co., Ltd. (2) · Ono Pharmaceutical Co. Ltd (2)
Often tested with
Tested in the same studies.
Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tamnorzatinib.
Studies
Open first, then newest update. How each study uses tamnorzatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06532331Written as ONO-7475
- Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerCompletedPhase 1Ono Pharmaceutical Co., Ltd.NCT06525246Written as ONO-7475
- A Study of ONO-7475 in Patients With Acute LeukemiasTerminatedPhase 1/2Ono Pharmaceutical Co. LtdNCT03176277Written as ONO-7475 3mg once daily
- Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedPhase 1Ono Pharmaceutical Co. LtdNCT03730337Written as ONO-7475
Codes
What other systems call tamnorzatinib · ClinicalTrials.gg INT014238
- UNII (FDA) 0VCB95RHRVTAMNORZATINIBOne source FDA
- NCI Thesaurus C136822TamnorzatinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0VCB95RHRV | TAMNORZATINIB | One source FDA |
| NCI Thesaurus | C136822 | Tamnorzatinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.